BSE: 532488
To view real time prices Login to your account
Already an existing customer? - Login Now!
BSE Click here to view BSE data
Live Chart
Loading, Please wait...
Error in Fetching Data, Please retry later.
No data available.
MKT Cap:
52-wk High:
52-wk Low:
Prev close:
Div yield:

Fundamental analysis


0 250 500 750 1 000
Financial trend

What is not working for the company?

What is working for the company?

Underperformed both Sector by -9.08% and Sensex by -20.92%
MARKET CAP (Large Cap Stock)Rs 89,115 Cr
PE (TTM) 29.77
PE Ratio29.77
Price to Book Value7.34
EV to EBIT25.68
EV to EBITDA23.37
EV to Capital Employed9.74
EV to Sales9.40
PEG Ratio0.74
Dividend Yield0.89%
ROCE (Latest)37.94%
ROE (Latest)24.66%
NameDec 22Sep 22
Promoters (Change:-0.00) 51.94%51.94%
FIIs (Change:-0.25) 15.15%15.4%
Mutual Funds (Change:-0.94) 12.68%13.62%
Insurance Companies (Change:0.95) 6.76%5.81%
Other DIIs (Change:-0.12) 1.23%1.35%
Non Institution (Change:0.36) 12.24%11.88%

Similar Stocks

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

If I had made LUMPSUM investment of ₹ 1,00,000


Months ago

My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %


Frequently Asked Questions

What is the Share price of DIVI'S LABORATORIES LTD. (DIVISLAB)?

DIVI'S LABORATORIES LTD. (DIVISLAB) share price as of February 2, 2023, on NSE is Rs 3,267.00 (NSE) and Rs 3,271.90 (BSE) on BSE.


Yes, You can buy DIVI'S LABORATORIES LTD. (DIVISLAB) shares by opening a Demat account with Angel One.

How do I buy DIVI'S LABORATORIES LTD. (DIVISLAB) from Angel One?

DIVI'S LABORATORIES LTD. (DIVISLAB) share can be brought through the following modes:
  1. Direct investment: You can buy DIVI'S LABORATORIES LTD. (DIVISLAB) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to DIVI'S LABORATORIES LTD. (DIVISLAB) shares.

In which sector do DIVI'S LABORATORIES LTD. (DIVISLAB) belong?


What is the total Asset of Divis Lab?

The total asset of Divis Lab is Rs. 13,360 Crores.

What is the main business of Divis Lab?

The business produces top generic chemicals used as nutraceutical components and produces APIs and intermediates on demand for prominent international innovation firms.

Who is the owner of Divis Lab?

The owner of Divis Labs is Divi Murali. He is the Chairman and CEO of Divis Laboratories.

Who are the promoters of Divis Lab?

The promoters are Nilima Motaparti, Satchandra Kiran Divi, Nilima Prasad Divi, Swarna Latha Divi, Divi’S Biotech Private Limited, Murali Krishna Prasad Divi, Madhusudana Rao Divi, Babu Rajendra Prasad Divi, Radhakrishna Rao Divi.


Today's live share price for DIVI’S LABORATORIES LTD is NSE: ₹ 3,267.00, BSE: ₹ 3,271.90 with a current market capitalization of .

Divi`s Laboratories Ltd is an India based manufacturer of Active Pharmaceutical Ingredients (APIs) and Intermediates. The company is engaged in manufacture of generic APIs, custom synthesis of active ingredients and other specialty chemicals, such as peptides and nutraceuticals. The company has three multi-purpose manufacturing facilities with a total reactor capacity of 4,500 cubic meter and all support infrastructures, such as Utilities, environment management and safety systems. The company`s main manufacturing and research and development facilities are located in the State of Andhra Pradesh, India. The company has two subsidiaries: Divis Laboratories (USA) Inc and Divi`s Laboratories Europe AG after marketing of Neutraceutical products in North American and European Countries. Divi`s Laboratories Ltd was established in the year 1990 as Divis Research Center (DRC) with Research & Development as their prime fundamental. During the year 1991-93, the company successfully developed several commercial processes for intermediates and bulk actives and supplies to manufacturing majors. In the year 1994, they changed their name to Divis Laboratories Ltd to reflect their growing area of operations. In the year 1995, the company started operations in their manufacturing facility (Unit I) at Choutuppal near Hyderabad. In the year 1997, the company was certified as ISO-9002 compliant by SGS-Yarsley of U.K. In the year 1999, European Directorate gave a "Certificate of Suitability" (CoS) for Naproxen produced by the company. In the year 2001, the company received OHSAS-18001 Certification from BVQI of London for their Occupational Health and Safety Management Systems. In the year 2002, the company commenced setting up of their second manufacturing facility (Unit II) at Chippada near Visakhapatnam. In the year 2003, they opened a new research center christened "DRC-Vizag" for fundamental research in selected niche business core segments. The company went for initial public offering (IPO) and their shares were listed on Bombay Stock Exchange and National Stock Exchange. In the year 2004, the company invested an amount of Rs 3035.21 lakh towards capital expenditure at their manufacturing facilities at Choutuppal (Unit-I) and Chippada (Unit-II) for additional machinery installed at both Unit-I and Unit-II. In the year 2006, the company received letter of approval from Ministry of Commerce, Government of India, for setting up a sector-specific special economic zone (SEZ) for pharmaceutical ingredients at Chippada, Bheemunipatnam in Visakhapatnam with investment of Rs 200 crore. The company`s second manufacturing site at Chippada, was converted into Export Oriented Unit (EOU) and started operations as EOU from June 1, 2006. During the year 2006-07, the company developed an SEZ titled "Divi`s Pharma SEZ" on a 250-acre site at Chippada, Visakhapatnam. During the year 2007-08, the company set up new production as well as utility facilities in SEZ and EOU Units, and enhanced existing capacities at Unit-1. They commissioned Nutraceuticals Manufacturing facility at Divi`s Pharma SEZ and commenced commercial operations effective June 1, 2008. During the year 2008-09, the company added 9 products to their product portfolio of which 4 are generic APIs and intermediates and 5 are custom synthesis APIs and intermediates. During the year 2009-10, they added 7 products to their product portfolio of which 2 are generic APIs and intermediates and 5 are custom synthesis APIs and intermediates. During the year 2010-11, the company added 21 products to their product portfolio of which 8 are generic APIs and intermediates and 13 are custom synthesis APIs and intermediates. The company set up a new facility called "DSN SEZ Unit" at Chippada in Visakhapatnam at an estimated cost of Rs 200 crore for creating additional capacities for the new opportunities in generic as well as custom synthesis segment. The DSN SEZ Unit commenced commercial operations from June 1, 2011.

Read more

Enjoy Zero Brokerage on Equity Delivery

Join our 1 Cr+ happy customers